Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP000036

Drug Information
NameNeomycin    
SynonymsAntibiotic produced by Streptomyces decaris. Neomycin B; NEOMYCIN SULFATE; D-Streptamine, O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1.->3)-O-.beta.-D-ribofuranosyl-(1->5)]-O-[2,6-diamino-2,6-dideoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy; BDG-(1-4)NEB-(5-1)RIB-(3-1)NED; HSDB 3242; Neomycinum; NCGC00179612-01; AB00443887; Framycetine; Myacyne; D-Streptamine, O-2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1-4)-O-(O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1-3)-beta-D-ribofuranosyl-(1-5))-2-deoxy-; 4-18-00-07476 (Beilstein Handbook Reference); UNII-I16QD7X297; Vonamycin powder V; Neomicina; 1393-86-8; DB00452; CID8378; Fraquinol; BRN 0101621; Framicetina [INN-Spanish]; EPA Pesticide Chemical Code 006303; ST075177; Framycetin [INN:BAN:DCF]; PIMAVECORT; C25H50N6O13; Actilin; Neomycin solution; 1405-10-3 (sulfate (salt)); Fradiomycin B; Antibiotic 10676; CHEBI:7508; Neomcin; N1142_SIGMA; LS-96091; Neobrettin; 72131_FLUKA; Soframycin; Soframycin Ophthalmic; Neomycinum [INN-Latin]; HMS2089P15; D05140; EINECS 215-766-3; Antibiotique; USAF CB-19; EINECS 204-292-2; CCRIS 5462; Neomycine; Prestwick3_000158; 119-04-0; Neomycin B sulfate; MolPort-003-938-736; BSPBio_000296; NMY; DB00994; LS-96095; Enterfram; AC1L1QVH; UNII-4BOC774388; Neo-Rx; BDG-(1-4)CYY-(5-1)RIB-(3-1)IDG; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside; Neolate; BPBio1_000326; 1404-04-2; C01737; NEOMYCIN AND POLYMYXIN B SULFATES; Neomas; (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol; Fradiomycin; Framycetin; Framycetin (INN); Neomin; Myciguent; Caswell No. 595; Fradiomycinum; Actiline; Nivemycin; Framycetine [INN-French]; 11025-81-3; Endomixin; neomycin; Framicetina; Neomicina [DCIT]; C23H46N6O13; Framycetinum; Soframycine; VONAMYCIN; Neo-Fradin; NEOMYCIN B; Tuttomycin; Mycifradin; Framycetinum [INN-Latin]; Myacine; Neomycine [INN-French]; Framygen; Neobiotic    
Trade NameMycifradin; Neo-Fradin; Neo-Tab    
CompanyGeofman    
IndicationAcute hepatic failure and alcoholic cirrhosis of the liverApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassAnti-Bacterial Agents    
CAS NumberCAS 1404-04-2
FormularC23H46N6O13    
PubChem Compound IDCID 8378.    
PubChem Substance IDSID 4872.    
SuperDrug ATC IDA01AB08;    
SuperDrug CAS ID001404042;    
Target30S ribosomal subunitBinder[2]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 060304 To Reference
Ref 2Characterization of a 30S ribosomal subunit assembly intermediate found in Escherichia coli cells growing with neomycin or paromomycin. Arch Microbiol. 2008 May;189(5):441-9. Epub 2007 Dec 5. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543